Probiotic Exopolysaccharide Shows Antioxidant and Antidiabetic Activity

Researchers characterized a polysaccharide from Lactiplantibacillus plantarum RSM51 and tested its effects on antioxidant and digestive enzyme activity.

Updated on Nov. 18, 2026 in Life Sciences

A clear glass flask of cloudy amber liquid with translucent strands floating in it, set on a steel stand against a plain gray wall.
Researchers characterized an exopolysaccharide produced by the probiotic strain Lactiplantibacillus plantarum RSM51, finding moderate antioxidant activity and enzyme inhibition in laboratory assays. AI Illustration. Upload story photo >

Researchers sequenced the genome of Lactiplantibacillus plantarum RSM51 and characterized an exopolysaccharide it produces, finding moderate antioxidant activity and inhibition of alpha-amylase and alpha-glucosidase. The findings were reported in laboratory analysis of the strain.

Why it matters

Exopolysaccharides from lactic acid bacteria are studied for potential functional-food and therapeutic uses, and this work links a specific gene-level biosynthesis profile to measurable bioactivity. The results remain preliminary and come from laboratory assays rather than human trials.

The study reports a 3.37 Mbp assembled genome with 44.35% GC content and a crude exopolysaccharide yield of approximately 410 mg/L, but the activity values are crude-extract measurements. Whether these inhibition levels are comparable to established drugs or hold for purified compounds is not addressed.

The details

Researchers screened the sequenced genome for gene clusters tied to exopolysaccharide biosynthesis, predicting enzymes for glycosyltransferases, polymerization and transport. Fourier-transform infrared spectroscopy indicated a polysaccharide structure, and scanning electron microscopy showed an irregular, porous, amorphous morphology.

The Big Picture

The work builds on a substantial body of research into Lactiplantibacillus plantarum exopolysaccharides as functional bioactive compounds. It adds genome-level biosynthesis analysis to the bioactivity data that earlier strain-characterization studies have typically reported separately.

Any practical use of such compounds would depend on purification, safety testing and clinical validation, which this laboratory study does not address. Readers should not treat these crude-extract results as evidence of a dietary or therapeutic benefit.

The takeaway

Laboratory results on a bacterial polysaccharide are an early step, and their translation into food or medicine requires purified-compound testing and human studies. Treat such findings as research leads rather than established health benefits.

Further reading

Explore more Life Sciences coverage for broader context on microbial research.

Source note: This article includes information reported by Nature.